Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Sareum Holdings plc

November 20, 2006
Multi-Target Genentech Collaboration
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, has entered into a multi-target research services agreement with Genentech, Inc., a leading biotechnology company. The 12 month agreement includes research fees and milestone payments in excess of $1.5M, plus an option to extend for a further 12 months. More

October 9, 2006
Research Collaboration with PIramed Ltd
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce today that it has entered into a significant research collaboration with PIramed Ltd, a privately owned UK biotechnology company, to discover novel, targeted drug therapies for the treatment of immune inflammatory diseases. More

September 26, 2006
Cancer Collaboration with Roche
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce that it has entered into a collaborative agreement with Roche, one of the world’s leading research-oriented healthcare groups, to provide protein structure determination capabilities to accelerate Roche’s cancer drug discovery research. More

September 4, 2006
RESULTS FOR THE TWELVE MONTHS ENDED 30 JUNE 2006
Financial highlights:
– Revenues increased 440% to £1.5M (2005: £0.3M)
– Loss on ordinary activities for period (after taxation) reduced 50% to £0.6M (2005: £1.2M)
– Loss on ordinary activities Jan-June 2006 (after taxation) reduced 96% to £22,000 (2005: £631,000)
– Exercise of £500,000 Put and Call option
– Cash in bank increased 20% to £528,000 (2005: £441,000)


More

August 31, 2006
NOVEL COMPOUNDS DISCOVERED IN CANCER DRUG DISCOVERY COLLABORATION
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce that substantial progress has been made in its joint cancer drug discovery collaboration with The Institute of Cancer Research (The Institute) and Cancer Research Technology Limited (CRT). More

August 15, 2006
Second Collaboration with H. Lundbeck A/S
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce that it has entered into a second collaborative agreement with H. Lundbeck A/S (Copenhagen: LUN). More

June 23, 2006
Collaboration with Sirtris Pharmaceuticals
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce that it has entered into a collaborative agreement with Sirtris Pharmaceuticals (Sirtris), based in Cambridge, MA, USA. In this collaboration, Sareum will apply its expertise in high throughput protein expression, purification and structure determination to accelerate drug discovery research at Sirtris. More

June 8, 2006
Success Milestones Reached in Collaboration with Schering AG
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce the achievement of key success milestones in its collaboration with Schering AG (FSE: SCH, NYSE: SHR). More

February 23, 2006
FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2005
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery and services business, is pleased to announce its financial results for the six month period ended 31 December 2005. More

February 9, 2006
$5M RESEARCH COLLABORATION WITH IDENIX PHARMACEUTICALS, INC.
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery and services business, is pleased to announce that it has entered into a collaborative research agreement with Idenix Pharmaceuticals, Inc (Idenix) to discover novel hepatitis C compounds. Idenix is based in Cambridge, Mass, USA, and is engaged in the discovery, development and commercialization of innovative anti-viral therapeutics. More

January 17, 2006
ORGANON AND SAREUM ANNOUNCE RESEARCH COLLABORATION IN AUTOIMMUNE DISEASE
January 17, 2006, Oss, The Netherlands, and Cambridge, UK - Organon, the human health care business unit of Akzo Nobel and Sareum Holdings plc, the specialist structure-based drug discovery and services business, today announced a collaborative research agreement. More

October 27, 2005
SAREUM ANNOUNCES COLLABORATION WITH SCHERING AG
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery and services business, is pleased to announce that it has entered into a collaborative agreement with Schering AG, Germany (FSE: SCH, NYSE: SHR), a global research-based pharmaceutical company with sales in excess of $6 Billion in 2004. The aim of the collaboration is for Sareum to provide protein structure determination capabilities to accelerate drug discovery research at Schering. More

July 25, 2005
MAJOR CANCER DRUG DISCOVERY COLLABORATION
Sareum Holdings plc (Sareum) (AIM: SAR), the specialist structure-based drug discovery and services business, The Institute of Cancer Research (The Institute), Europe's leading cancer research centre, and Cancer Research Technology Limited (CRT), the oncology focused development and commercialisation company, are pleased to announce that they have entered into a joint collaboration to develop novel cancer therapeutics. More

Data


26,807
Tech investments
From our Online Data Service
17,301
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Mar 23€2.0MInternet services
Mar 23€1.5MInternet services
Mar 23€110.0MInternet commerce
Mar 21€1.9MBusiness applications
Mar 20€1.0MInternet commerce
Mar 20€12.0ME-Commerce

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.